R. Andrew Ramelmeier

Chief Technology Officer at Adverum Biotech

No bio yet


Org chart


Teams


Offices

This person is not in any offices


Adverum Biotech

9 followers

Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration.


Industries

Employees

51-200

Links